13 completed, 4 not yet recruiting, 3 active not recruiting, 3 recruiting. 31 Phase 3, 12 Phase 2.
Follow Hypopigmentation: new trials by email Literature Review of Hypopigmentation trials Research Report on Hypopigmentation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mitochondrial Network Modulation Approach Using Hyperbaric Oxygen (HBO) Therapy and Nb-UVB for Treating Vitiligo OXYGENE MEDICINAL LIQUIDE AIR PRODUCTS MEDICAL - Vitiligo Vulgaris | Phase 2 / Phase 3 | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 5 | 2026-09-01 | 2026-06-05 |
| A Phase III Clinical Study to Evaluate the Efficacy and Safety of MH004 Ointment in Non-segmental Vitiligo MH004 1.0% Ointment, MH004 Placebo Ointment - Vitiligo | Phase 3 | Recruiting | Minghui Pharmaceutical (Hangzhou) Ltd | 405 | 2026-08-04 | 2026-08-11 |
| Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo Ruxolitinib 1.5% Cream BID - Vitiligo | Phase 3 | Not yet recruiting | The Children's Hospital of Zhejiang University School of Medicine | 20 | 2026-06-01 | 2026-05-19 |
| Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study NB-UVB combined with microneedling and topical 10% secretome, receives NB-UVB combined with intradermal secretome injection, NB-UVB alone - Vitiligo | Phase 2 / Phase 3 | Not yet recruiting | Yohanes Firmansyah, dr, MH, MM | 150 | 2026-03-18 | 2026-04-03 |
| Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical Tacrolimus Ruxolitinib Cream 1.5%, Aqueous cream - Vitiligo | Phase 2 / Phase 3 | Recruiting | Hospital Authority, Hong Kong | 20 | 2024-11-29 | 2024-12-05 |
| Vitiligo, New Treatment and Serum s100B Baricitinib, oral mini pulse, Narrow Band UVB Treatment - Vitiligo, Generalized | Phase 2 / Phase 3 | Recruiting | South Valley University | 50 | 2024-10-02 | 2025-01-10 |
| A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo Ritlecitinib, Ritlecitinib 100 mg, Placebo - Vitiligo | Phase 3 | Active not recruiting | Pfizer | 394 | 2024-01-19 | 2026-09-28 |
| A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy - Vitiligo | Phase 3 | Active not recruiting | AbbVie | 614 | 2023-12-19 | 2026-06-09 |
| A Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet (NB-UVB) Light Versus NB-UVB Light Alone in Patients With Vitiligo Afamelanotide and NB-UVB Light, NB-UVB Light - Vitiligo | Phase 3 | Active not recruiting | Clinuvel, Inc. | 200 | 2023-10-11 | 2025-07-08 |
| Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST Imatinib Mesylate, Local resection - Gastrointestinal Stromal Tumor of Rectum | Phase 3 | Not yet recruiting | Fujian Medical University Union Hospital | 23 | 2023-10-01 | 2023-08-01 |
| Comparative Study Between Topical 5-fluorouracil and Latanoprost in Vitiligo. Latanoprost 0.005% Ophthalmic Solution, 5Fluorouracil - Vitiligo | Phase 2 / Phase 3 | Completed | South Valley University | 40 | 2022-03-15 | 2023-07-11 |
| Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo ruxolitinib, Vehicle - Vitiligo | Phase 3 | Completed | Incyte Corporation | 458 | 2020-09-24 | 2025-08-14 |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment Masitinib, Placebo, Best Supportive Care - Indolent Systemic Mastocytosis | Phase 3 | Unknown | AB Science | 140 | 2020-07-01 | 2023-05-06 |
| Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo Low Dose SHR0302 Ointment BID, High Dose SHR0302 Ointment BID, Placebo Comparator: Vehicle - Vitiligo | Phase 2 / Phase 3 | Terminated | Reistone Biopharma Company Limited | 75 | 2020-01-29 | 2022-07-13 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) Ruxolitinib cream, Vehicle - Non-segmental Vitiligo | Phase 3 | Completed | Incyte Corporation | 344 | 2019-10-03 | 2025-08-22 |
| Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1) Ruxolitinib cream, Vehicle - Non-segmental Vitiligo | Phase 3 | Completed | Incyte Corporation | 330 | 2019-09-20 | 2025-08-22 |
| Microneedling and Latanoprost in Acrofacial Vitiligo Latanoprost, Microneedling - Vitiligo | Phase 2 / Phase 3 | Unknown | Sohag University | 70 | 2018-09-01 | 2018-08-28 |
| Efficacy of Tacrolimus in Adults With Facial Non-segmental Vitiligo - VITAC tacrolimus, Placebo - Vitiligo | Phase 3 | Completed | University Hospital, Bordeaux | 42 | 2016-02-23 | 2021-04-19 |
| Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Needling, Triamcinolone - Vitiligo | Phase 2 / Phase 3 | Terminated | Rutgers, The State University of New Jersey | 22 | 2014-09-01 | 2017-07-25 |
| Evaluation of Non-cultured Epidermal Cellular Grafting vs Hyaluronic Acid for Repigmenting Vitiligo and Piebaldism VITICELL, PLACEBO - Vitiligo, Piebaldism | Phase 3 | Completed | Laboratoires Genévrier | 38 | 2014-04-29 | 2019-10-14 |
Showing 20 of 31. Sign in to see all of them.
Vitiligo (28) · Piebaldism (4) · Blushing (2) · Mastocytosis (2) · Mastocytosis, Systemic (2) · Pruritus (2) · Facies (1) · Gastrointestinal Stromal Tumors (1) · Pigmentation Disorders (1)
Skin Diseases (31) · Skin and Connective Tissue Diseases (31) · Pigmentation Disorders (30) · Albinism (4) · Amino Acid Metabolism, Inborn Errors (4) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Eye Diseases, Hereditary (4) · Genetic Diseases, Inborn (4) · Metabolic Diseases (4) · Metabolism, Inborn Errors (4) · Nutritional and Metabolic Diseases (4) · Pathological Conditions, Signs and Symptoms (4) · Skin Diseases, Genetic (4) · Neoplasms (3)
Latanoprost (2) · Percutaneous Collagen Induction (2) · Tacrolimus (2) · masitinib (2) · ruxolitinib (2) · Cell Transplantation (1) · Cell- and Tissue-Based Therapy (1) · Fluorouracil (1) · Imatinib Mesylate (1) · Lasers, Excimer (1) · Mastectomy, Segmental (1) · Ointments (1) · Ophthalmic Solutions (1) · Phototherapy (1) · Secretome (1)
Centre Hospitalier Universitaire de Nice (5) · Incyte Corporation (3) · AB Science (2) · Henry Ford Health System (2) · South Valley University (2) · AbbVie (1) · Ache Laboratorios Farmaceuticos S.A. (1) · Clinuvel, Inc. (1) · Fujian Medical University Union Hospital (1) · Hospital Authority, Hong Kong (1) · Istituti Fisioterapici Ospitalieri (1) · Laboratoires Genévrier (1) · Minghui Pharmaceutical (Hangzhou) Ltd (1) · Oslo University Hospital (1) · Pfizer (1)
France (14) · United States (10) · China (6) · Germany (6) · Poland (6) · Bulgaria (5) · Canada (5) · Italy (5) · Spain (5) · Netherlands (4) · United Kingdom (3) · Belgium (2) · Egypt (2) · Japan (2) · South Korea (2)
Kathleen Butler, MD (3) · Iltefat H Hamzavi, MD (2) · Babar Rao, MD (1) · Cristina Bulai Livideanu, MD, MSc (1) · Eli Johanne Nordal, MD (1) · Hassan M Ibrahim, professor (1) · Hossein Baharvand, PhD (1) · Mauro Picardo, MD (1) · Michael Jansen Politan (1) · Nanja Van Geel, Pr (1) · Nasser Aghdami, MD., PhD (1)
PMID 41125994, PMID 36260792, PMID 40156697, PMID 20364383, PMID 28069279, PMID 33549606, PMID 36048877, PMID 39078582, PMID 42171987, PMID 42594914
2019 (2), 2023 (2), 2016 (1)